Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03MPD
|
|||
| Drug Name |
PMID27019002-Compound-20a
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ORYZON GENOMICS SA [ES]
|
|||
| Structure |
 |
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysine-specific histone demethylase 1 (LSD) | Target Info | Inhibitor | [1] |
| Monoamine oxidase (MAO) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Lysine-specific histone demethylase 1 (LSD) | Target's Patent Info | [1] | |
| Monoamine oxidase (MAO) | Target's Patent Info | [1] | ||
| Pathway Interaction Database | Notch signaling pathway | |||
| Coregulation of Androgen receptor activity | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | HDACs deacetylate histones | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| Factors involved in megakaryocyte development and platelet production | ||||
| WikiPathways | Factors involved in megakaryocyte development and platelet production | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.